UK earnings, trading statements calendar - next 7 days
19th Mar 2026 14:38
Oxford BioMedica PLC - Oxford, England-based gene and cell therapy developer - Enters a five-year licensing and option agreement with Viral Vector Manufacturing Facility, an Australian contract development and manufacturing organisation (CDMO) and "the country's first commercial manufacturing facility of its kind", having signed a non-binding terms sheet in October. VVMF will have a non-exclusive global licence to use Oxford BioMedica's inAAVate platform "know-how and intellectual property", and an option to extend the licence to the LentiVector platform. OXB says it will receive a low single-digit million licence fee and is eligible for future platform use payments. Expects the contract to enable VVMF "to accelerate its operational and commercial readiness to provide advanced viral vector technologies to customers, capturing global demand with a particular focus on the fast-growing APAC region, and positioning Australia as a regional hub for high‑quality cell and gene therapy manufacturing." Read More
(Alliance News) - EQT Fund Management SARL confirmed on Wednesday it has no intention of making an offer for Oxford BioMedica PLC. Read More
(Alliance News) - Oxford BioMedica PLC on Tuesday said it expects to report revenue at the upper end of guidance as contracted orders increased. Read More
(Alliance News) - Oxford BioMedica PLC on Wednesday said it has signed a new commercial supply deal with Bristol-Myers Squibb Co. Read More
Oxford BioMedica PLC - Oxford, England-based gene and cell therapy developer - Says it notes recent press speculation and that it has received an unsolicited approach, regarding a possible cash takeover offer, from EQT X EUR SCSp and EQT X USD SCSp, funds managed by EQT Fund Management Sarl. Says it and EQT are in preliminary discussions to explore whether EQT could make a proposal which OXB's board would want to recommend. Previous unsolicited proposals from EQT have been rejected, as OXB's board believed they undervalued it and its prospects. Company "strongly" advises shareholders to take no action at this time. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and on Thursday: Read More
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and on Monday: Read More
(Alliance News) - The following London-listed shares received analyst recommendations on Monday morning and on Friday: Read More
(Alliance News) - Oxford BioMedica PLC on Tuesday said it has closed a deal to acquire a cell and gene therapy viral vector manufacturing facility in Durham, North Carolina. Read More
(Alliance News) - Oxford BioMedica PLC on Tuesday hailed its "strong revenue pipeline" and growth visibility, as it kept its financial outlook for the full-year unaltered. Read More
(Alliance News) - European stocks opened higher on Tuesday as gold prices continued to climb, with investors flocking to the safe-haven metal in anticipation of further future US rate cuts and a softer dollar. Read More
(Alliance News) - Burberry Group PLC and Metlen Energy & Metals PLC have been promoted to the FTSE 100 in its latest quarterly shuffle, with Taylor Wimpey PLC and Unite Group PLC relegated from the benchmark index. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday: Read More
(Alliance News) - Metlen Energy & Metals PLC is set to join the FTSE 100 at the first time of asking, at the expense of housebuilder Taylor Wimpey PLC, data from FTSE Russell suggested on Tuesday. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and on Friday: Read More
(Alliance News) - Stocks were called to open lower on Tuesday, while in corporate news British American Tobacco's chief financial officer is stepping down. Read More
(Alliance News) - Oxford BioMedica PLC on Friday said it has raised GBP60 million through a share placing and subscription to support expansion in the US and boost process productivity. Read More
(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Friday. Read More
Oxford Biomedica PLC - Oxford, England-based gene and cell therapy developer - Says it has a new loan facility with Oaktree Capital Management LP worth up to USD125 million over four years. Expects USD60 million upfront funding to be available when the deal closes. Plans to use this to repay an existing USD50 million loan from Oaktree. Notes that the loan includes option to draw down further USD25 million and additional USD40 million, subject to revenue targets. Says this increases flexibility to grow global contract development and manufacturing operations. Notes also that the loan will not amortise, with the full aggregate principal and outstanding amount due in 2029. Read More